Mar 2, 2010 - The University of Texas at Austin, College of Pharmacy, 2409 ...... 50%; use of FTC relative to 3TC increa
ABSTR AC T S
Abstracts from Professional Poster Presentations at AMCP’s 22nd Annual Meeting & Showcase
T
he following poster presentations have been prepared for the Academy of Managed Care Pharmacy’s 22nd Annual Meeting & Showcase, April 7-10, 2010, in San Diego, California. Poster presentations are selected by the AMCP Program Planning and Development Committee from proposals that are submitted to AMCP. Authors of posters are responsible for the accuracy and completeness of the data presented in the posters and in the abstracts published here. For more information about the studies described below, please contact the corresponding authors, indicated by an asterisk (*), whose addresses are listed in full. The names of the individuals who are scheduled to present at the meeting are in shown in bold. ■■ Adherence and Persistence with Duloxetine and Hospitalization in Patients with Major Depressive Disorder Liu X,* Tepper P, Watson PR. Eli Lilly and Company, Lilly Corporate Center, DC 4123, Indianapolis, IN 46285;
[email protected], 317.433.4006 BACKGROUND: Adherence to medication therapy for a sufficient duration is important in the treatment of major depressive disorder (MDD), since poor adherence may be associated with relapse and increased costs. Duloxetine is a new selective serotonin and norepinephrine reuptake inhibitor that has been approved for acute and maintenance treatment of MDD. OBJECTIVE: To examine the association between adherence and persistence with duloxetine and psychiatric and nonpsychiatric hospitalizations in the 1-year follow-up period after initiation. METHODS: In a large U.S. commercial managed care claims database, 4,542 patients with at least 1 claim with a diagnosis of MDD (ICD-9-CM codes 296.2 and 296.3) were initiated on duloxetine during 2006. All of the patients had no active prescription of duloxetine for 6 months prior to initiation and had continuous enrollment for 12 months prior to and after duloxetine initiation. Adherence for the first 6 months after study medication initiation was defined as Medication Possession Ratio (MPR) ≥ 0.8, and persistence was defined as the length of therapy without exceeding a 30-day gap. Logistic regression analyses were performed to examine the associations between adherence and persistence with duloxetine and psychiatric and non-psychiatric hospitalizations in the 1-year follow-up period. RESULTS: Overall, 53.9% of patients were adherent to duloxetine treatment; average length of treatment was 116.0 days (SD = 63.5) during the first 6 months after initiation. Compared with nonadherent patients, adherent patients had significantly lower rates of psychiatric (5.9% vs. 10.2%, P
